Corbus Pharmaceuticals’ Second Quarter 2020 Earnings Conference Call and Webcast Replay Now Available

Webcast Replay

Our CommitmentOur Commitment

We are committed to developing and commercializing therapeutics that improve the health of people affected by chronic inflammatory and fibrotic diseases.

Learn More

Our CompanyOur Company

We are a clinical-stage company focused on treating inflammatory and fibrotic diseases by targeting the endocannabinoid system.

Learn More

Our ScienceOur Science

Our focus on the endocannabinoid system is backed by an ever-expanding body of research and robust underlying science based on the endocannabinoid system as a master regulator of inflammation and fibrosis in the body.

Learn More

Leading Endocannabinoid System-Targeting Pipeline

2

Lead Compounds

3

Ongoing Late-Stage Clinical Studies

600+

Compounds in Library

>350k

People Affected by Target Diseases

Join Our Team

We are high achievers, creative, innovative and above all else, passionate about what we do.

View Open Positions
A group photo of our team

Sign up for
Email Alerts

Receive breaking news first!

Sign up today

Investor
Presentation

Third-party websites are provided for convenience only. Corbus Pharmaceuticals Holdings, Inc. does not approve of, or endorse any of the content. Corbus Pharmaceuticals Holdings, Inc. does not maintain, control or monitor the content of third-party websites in any way.